Key Considerations for Novo Nordisk A/S Investors

By Scott Lee • Monday, April 21 15:10 • Permanent Link

Join us for a quick overview of Novo Nordisk A/S, a Pharmaceutical company whose shares moved 0.1% today. Here are some facts about the stock that should help you see the bigger picture:

Novo Nordisk A/S has moved -53.6% over the last year, and the S&P 500 logged a change of 5.4%
NVO has an average analyst rating of buy and is -43.38% away from its mean target price of $102.64 per share
Its trailing earnings per share (EPS) is $3.42
Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 17.0 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $4.07 and its forward P/E ratio is 14.3
The company has a Price to Book (P/B) ratio of 1.8 in contrast to the S&P 500's average ratio of 4.74
Novo Nordisk A/S is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
NVO has reported YOY quarterly earnings growth of 29.2% and gross profit margins of 0.8%
The company has a free cash flow of $61.99 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.